Literature DB >> 27647396

[Current status and future prospect of internal medicine treatment for advanced esophageal cancer].

F Wang1, Q X Fan1.   

Abstract

Esophageal cancer (EC) is one of common malignant tumors, and the incidence and mortality of EC in China rank the first place in the world. Because of the occult onset, the early atypical symptoms, and the lack of effective early diagnostic methods, most of patients are diagnosed at an advanced stage of the disease and lost the chance of surgery. Comprehensive treatment including palliative medical treatment, molecular targeted therapy, immunotherapy and so on is appropriate for these patients. How to choose the chemotherapy regimen and formulate reasonable treatment plan has become a hot spot in clinical research. Molecular targeted drugs have become a new developmental direction in cancer treatment because of their high specificity and antitumor activity, but the effects on esophageal cancer remain controversial. With the development of immune check point blockade treatment, breakthrough has been made in tumor immunotherapy, which has become an important means in cancer comprehensive treatment and shown a good prospect of treatment.

Entities:  

Mesh:

Year:  2016        PMID: 27647396     DOI: 10.3760/cma.j.issn.0253-3766.2016.09.004

Source DB:  PubMed          Journal:  Zhonghua Zhong Liu Za Zhi        ISSN: 0253-3766


  2 in total

1.  The Application and Influence of Hospice Care Among Patients with Advanced Esophageal Cancer.

Authors:  Zheng-Fang Li; Meng-Jie Liu
Journal:  Int J Gen Med       Date:  2021-10-15

2.  Sulforaphene induces apoptosis and inhibits the invasion of esophageal cancer cells through MSK2/CREB/Bcl-2 and cadherin pathway in vivo and in vitro.

Authors:  Chengjuan Zhang; Junxia Zhang; Qiong Wu; Benling Xu; Guoguo Jin; Yan Qiao; Simin Zhao; Yang Yang; Jinwen Shang; Xiaofang Li; Kangdong Liu
Journal:  Cancer Cell Int       Date:  2019-12-19       Impact factor: 5.722

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.